In Celexir’s immune-support lineup, NK Peptide is positioned for patients who need stronger frontline defense—those with chronic infections, signs of immune aging, or elevated oncology risk. The clinical intent is straightforward: bolster natural killer (NK) cell number and performance to improve early detection and clearance of abnormal or infected cells while maintaining overall immune balance.
Mechanistically, NK Peptide enhances NK cell activity, the innate arm responsible for rapid, non–antigen-specific responses. By reinforcing surveillance and cytotoxic function, it supports the body’s ability to recognize and eliminate compromised cells, adding a targeted innate layer to broader immune programs without broad immunosuppression.
From a longevity and resilience perspective, the value proposition is keeping innate immunity sharp as adaptive responses slow with age. NK Peptide is best integrated alongside sleep, metabolic, and inflammation management—positioned as an adjunct you can measure against objective markers like infection frequency, recovery time, and inflammatory trends.
Celexir delivery & specs: ready-to-use prefilled pen, 1–2 mg, twice weekly per protocol, >98% clinical-grade purity, 2–8 °C storage, and full compliance documentation (CoA/MSDS) for repeatable clinic workflows. These controls reduce variability from compounding and protect integrity from warehouse to administration.